Cargando…

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1(R132H) oncogene. We d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Diana D., Lee, Joyce H., Wang, Adam C., Khanal, Januka, Gao, Wenhua, Kaelin, William G., McBrayer, Samuel K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189469/ https://www.ncbi.nlm.nih.gov/pubmed/37149859 http://dx.doi.org/10.1016/j.xpro.2023.102281

Ejemplares similares

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
por: Shi, Diana D, et al.
Publicado: (2021)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model
por: Ruiz-Rodado, Victor, et al.
Publicado: (2022)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
por: Shi, Diana D., et al.
Publicado: (2022)

Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas
por: Mirchia, Kanish, et al.
Publicado: (2019)

PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS
por: Bornhorst, Miriam, et al.
Publicado: (2020)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

NI-1 METHYLTHIOADENOSINE PHOSPHOLYLASE STATUS CORRELATES WITH PROGNOSIS AND METHIONINE UPTAKE IN IDH MUTANT ASTROCYTOMA
por: Yamamura, Toshihiro, et al.
Publicado: (2022)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas
por: Hickman, Richard A., et al.
Publicado: (2023)

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant
por: Yano, Hirohito, et al.
Publicado: (2021)

IDH-mutant Astrocytoma Arising in the Brainstem with Symptom Improvement by Foramen Magnum Decompression: A Case Report
por: NAGASE, Takayuki, et al.
Publicado: (2023)

Naturopathic Treatment of Grade III Oligodendroglioma With Progression to Grade IV Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma and the Development of Spinal Gliomatosis
por: Terrani, Kristina F, et al.
Publicado: (2023)

Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
por: Suwala, Abigail K., et al.
Publicado: (2020)

FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas
por: Kinoshita, Manabu, et al.
Publicado: (2021)

Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
por: Zhao, Binghao, et al.
Publicado: (2022)

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
por: Tateishi, Kensuke, et al.
Publicado: (2023)

Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas
por: Grandin, Nathalie, et al.
Publicado: (2019)

Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas
por: Lasocki, Arian, et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant
por: Sohn, Beomseok, et al.
Publicado: (2021)

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma
por: Lin, Yi, et al.
Publicado: (2021)

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis
por: Stewart, James, et al.
Publicado: (2022)

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors
por: Chen, Wenlin, et al.
Publicado: (2023)

Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma
por: Minniti, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iutt72goqhk2r0tan2nt1dvgvk